Effects of Subanesthetic Concentrations of Nitrous Oxide - 1

NCT ID: NCT00000249

Last Updated: 2015-05-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

1993-09-30

Study Completion Date

1995-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To examine effects of subanesthetic concentrations of nitrous oxide on cold-pressor pain in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid-Related Disorders Substance-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes

Group Type NO_INTERVENTION

No interventions assigned to this group

20% N2O

Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 \& 30 minutes

Group Type ACTIVE_COMPARATOR

20% N2O

Intervention Type DRUG

20% inhaled N2O

30% N2O

Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes

Group Type ACTIVE_COMPARATOR

30% N2O

Intervention Type DRUG

30% inhaled N2O

40% N2O

Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes

Group Type ACTIVE_COMPARATOR

40% N2O

Intervention Type DRUG

40% inhaled N2O

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

20% N2O

20% inhaled N2O

Intervention Type DRUG

30% N2O

30% inhaled N2O

Intervention Type DRUG

40% N2O

40% inhaled N2O

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Please contact site for information.
Minimum Eligible Age

21 Years

Maximum Eligible Age

37 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

University of Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James Zacny, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Chicago, Anesthesia & Critical Care

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Pharmocol Biochem and Behavior 1995, 51( 2): 323-329

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DA008391

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01-08391-1

Identifier Type: -

Identifier Source: secondary_id

NIDA-08391-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Subcutaneous Lidocaine For Cancer-Related Pain
NCT01384877 COMPLETED PHASE2/PHASE3